89 phenotypes from 3 alleles in 10 genetic backgrounds

Allelic Composition Genetic Background	Annotated Term	Reference
C3tm1Crr/C3tm1Crr B6.129S4-C3tm1Crr	abnormal blastocyst morphology	J:150898
	abnormal blood homeostasis	J:113463
	abnormal dendritic spine morphology	J:224676
	abnormal female reproductive system physiology	J:150898
	abnormal hippocampus CA3 region morphology	J:224676
	abnormal inflammatory response	J:113463
	abnormal neutrophil morphology	J:113463
	abnormal spatial working memory	J:224676
	abnormal synaptic plasticity	J:224676
	abnormal synaptic vesicle number	J:224676
	brain inflammation	J:123658
	decreased anxiety-related response	J:224676
	decreased cerebral infarct size	J:123658
	decreased fetal weight	J:150898
	decreased placental labyrinth size	J:150898
	decreased spongiotrophoblast size	J:150898
	decreased susceptibility to autoimmune hemolytic anemia	J:145432
	enhanced contextual conditioning behavior	J:224676
	enhanced long-term potentiation	J:224676
	enhanced paired-pulse facilitation	J:224676
	enhanced spatial learning	J:224676
	impaired embryo implantation	J:150898
	increased neuron number	J:224676
	prolonged estrous cycle	J:150898
	small placenta	J:150898
C3tm1Crr/C3tm1Crr B6;129S4-C3tm1Crr/J	abnormal c-wave shape	J:214214
	abnormal eye electrophysiology	J:136745
	abnormal retina horizontal cell morphology	J:214214
	abnormal retina rod bipolar cell morphology	J:214214
	decreased b-wave amplitude	J:214214
	decreased circulating free fatty acids level	J:214214
	decreased susceptibility to Coronaviridae infection	J:286325
	increased susceptibility to bacterial infection	J:136745
	normal vision/eye phenotype	J:136745
C3tm1Crr/C3tm1Crr involves: 129S4/SvJae	abnormal blood coagulation	J:44715
	decreased susceptibility to alcohol-induced hepatic steatosis	J:128218
	decreased susceptibility to injury	J:128218
	decreased urine albumin level	J:44715
	glomerulonephritis	J:44715
C3tm1Crr/C3tm1Crr involves: 129S4/SvJae * C57BL/6	abnormal cell-mediated immunity	J:30152
	abnormal enzyme/coenzyme level	J:152533
	abnormal humoral immune response	J:64282
	abnormal immune system morphology	J:44240
	abnormal immune system physiology	J:44240
	abnormal induced morbidity/mortality	J:152533
	abnormal intestine morphology	J:78613
	abnormal liver morphology	J:152533
	abnormal liver physiology	J:152533
	abnormal mast cell physiology	J:44240
	abnormal spleen germinal center morphology	J:64282
	abnormal tumor necrosis factor level	J:44240
	decreased circulating alanine transaminase level	J:152533
	decreased circulating interleukin-6 level	J:152533, J:166640
	decreased circulating tumor necrosis factor level	J:152533
	decreased hepatocyte proliferation	J:152533
	decreased mast cell number	J:44240
	decreased neutrophil cell number	J:44240
	decreased osteoclast cell number	J:166640
	decreased spleen germinal center number	J:64282
	decreased spleen germinal center size	J:64282
	decreased susceptibility to injury	J:120567
	decreased vascular permeability	J:78613
	enhanced central nervous system regeneration	J:112353
	focal hepatic necrosis	J:152533
	hepatic steatosis	J:152533
	normal immune system phenotype	J:64282
	impaired liver regeneration	J:152533
	increased circulating alanine transaminase level	J:152533
	increased circulating bilirubin level	J:152533
	increased susceptibility to bacterial infection	J:30152, J:44240
	increased susceptibility to bacterial infection induced morbidity/mortality	J:205353
	increased susceptibility to induced morbidity/mortality	J:44240
	liver inflammation	J:30152
C3tm1Hrc/C3tm1Hrc B6.129-C3tm1Hrc	impaired complement alternative pathway	J:177350
	impaired liver regeneration	J:91917
C3tm1Hrc/C3tm1Hrc either: (involves: 129S2/SvPas * C57BL/6) or (involves: 129X1/SvJ * C57BL/6)	increased susceptibility to bacterial infection	J:56193
C3tm1Hrc/C3tm1Hrc involves: 129	abnormal intestinal lipid absorption	J:87945
	decreased body weight	J:87945
	decreased circulating insulin level	J:87945
	decreased circulating leptin level	J:87945
	decreased total body fat amount	J:87945
	increased circulating free fatty acids level	J:87945
	increased triglyceride level	J:87945
	polyphagia	J:87945
C3tm1Hrc/C3tm1Hrc involves: 129/Sv * C57BL/6	abnormal energy expenditure	J:58966, J:60633
	abnormal glucose homeostasis	J:58966, J:60633
	abnormal lipid homeostasis	J:58966, J:60633
	decreased body weight	J:60633
	decreased circulating glucose level	J:58966, J:60633
	decreased circulating insulin level	J:60633
	decreased circulating leptin level	J:58966, J:60633
	decreased circulating triglyceride level	J:60633
	decreased total body fat amount	J:58966, J:60633
	decreased white adipose tissue amount	J:60633
	increased brown adipose tissue amount	J:58966
	increased circulating free fatty acids level	J:58966, J:60633
	increased triglyceride level	J:58966
	polyphagia	J:58966, J:60633
C3tm1Pkna/C3tm1Pkna D1.129P2-C3tm1Pkna	decreased susceptibility to induced arthritis	J:88872
C3tm1Pkna/C3tm1Pkna involves: 129P2/OlaHsd * C57BL/6	no abnormal phenotype detected	J:45857